Top Picks In The Biotech Space: VRTX, GILD

Saumen Chattopadhyay says Gilead Sciences will remain the leader in Hepatitis C treatment, and will maintain a strong leadership position. He notes that driving growth for the company remains to be its solid HIV product portfolio, but that forward P/E multiples have compressed over the last year. For this reason, Vertex Pharmaceuticals is his top pick in the biotech space, as it now is trading below the historical average. Tom White then looks at example trades in both Vertex Pharmaceuticals and Gilead Sciences.

Morning Trade Live

18 Mar 2022

SHARE

ON AIR
7:00 am
Futures
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
ON AIR
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Market Overtime
REPLAY
education
7:30 pm
Your First Trade
REPLAY
8:00 pm
Trading 360
REPLAY
9:00 pm
Market Overtime
REPLAY
education
9:30 pm
Your First Trade
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now